From a Regulatory Perspective: Quality Control and Market Access of Helicobacter pylori Antigen Detection Kits (Colloidal Gold Method)

Product Classification and Registration Management

According to the current classification catalog of the National Medical Products Administration, Helicobacter pylori antigen detection kits (colloidal gold method) are generally managed as Class II medical devices, while some products claimed to be usable for auxiliary diagnosis or treatment monitoring may be classified as Class III. Applicants are required to submit product technical requirements, analytical performance evaluation (such as limit of detection, hook effect, cross-reactivity, precision, etc.), stability study data, and clinical evaluation reports. For products using the colloidal gold platform, the quality of antigen and antibody raw materials, labeling process, membrane material, and assembly process are all key control points.

Production Quality System and Key Parameters

Manufacturers shall establish a quality system compliant with the Good Manufacturing Practice for Medical Devices, covering raw material procurement, production process control, quality control, and finished product release. Factory inspection of kits with common specifications typically includes indicators such as appearance, membrane strip width, migration rate, positive coincidence rate, negative coincidence rate, and intra-batch repeatability. In terms of environmental conditions, the cleanliness of the production workshop is generally required to be no lower than Class 300,000, with relative humidity controlled between 20% and 60%. It should be noted that different manufacturers may have variations in cutting speed, membrane application process, etc., but batch-to-batch consistency must be maintained.

Clinical Evaluation and Performance Verification

In accordance with the Measures for the Registration and Filing Administration of In Vitro Diagnostic Reagents, such kits may be evaluated by comparison with marketed products of the same type, or by using gold standards (such as the 13C urea breath test, endoscopic pathology plus culture) as references. The clinical evaluation should include populations of different ages, genders, regions, and symptom distributions to evaluate their sensitivity and specificity in the real world. In addition, for products intended for post-treatment follow-up, the drug discontinuation interval and trend of result changes shall also be described. Absolute expressions such as "" and "100%" shall be avoided.

Post-Market Surveillance and Common Issues

After obtaining the registration certificate, manufacturers shall continuously conduct adverse event monitoring. Common issues include: false negatives (due to low bacterial load, antigen variation, or improper operation), false positives (due to sample contamination or non-specific binding), and test strip failure caused by improper storage. Medical institutions shall verify the expiration date and packaging integrity before use, and regularly perform internal quality control with quality control materials. Regulatory authorities also conduct periodic sampling of products on sale; if non-compliance with standard requirements is found, recall or rectification will be required.

Market Prospects and Compliance Recommendations

With the rising drug resistance rate of Helicobacter pylori and increasing demand for home self-testing, the market capacity of such kits continues to expand. When promoting products, manufacturers shall adhere to the scope of application stated in the product registration certificate and shall not make claims beyond the approved indications. Distributors are advised to prioritize enterprises with ISO 13485 certification or that have passed on-site inspection under China's medical device GMP. In terms of end-user education, clear operation videos or illustrated instructions should be provided to avoid misjudgment caused by improper sampling.